Developing a Target Product Profile for a Preventive HIV Vaccine
Topics to be Covered

• Overview of TPPs
  • What are they?
  • What is the purpose and benefit of using a TPP?
  • What is usually in a TPP?

• What are the unique issues for a TPP for HIV vaccines?
  • Comparisons with other vaccines

• How can a TPP best be used to support HIV vaccine development?
TPP Background and History

• In 1997, a working group with FDA and industry members recommended developing a template to:
  • summarize drug labeling concepts
  • focus drug development process
  • facilitate discussions between FDA and product developers

• This led to the development of the **Target Product Profile**
WHY?

From regulatory perspective, the product package insert (labeling) and the product claims must be supported by relevant studies and data.

In the past, companies would commonly request approval for indications or products that had not been included in the development plan.

Clinical data in men 18-30 years old may permit approval only for men 18-30 years old – not helpful if indication is primarily in men >50

Clinical studies demonstrating a reduction in pain may not support a labeling claim for reduction in associated disease symptoms – not helpful if pain reduction is considered insufficient for approval by regulatory agency.
TPP emphasizes the concept of beginning with the goal in mind.

The document should lay out the desired labeling claims – indication, target population, product characteristics.

These label claims should be used to design the studies that are needed to support the claims.
The TPP Today

- Original concept adopted and expanded beyond label claims
- Widely used by industry to assist and direct product development programs internally
- Emphasis remains on defining the goal in advance, and systematically working toward this goal
- Often includes criteria for “minimally acceptable target” and “desired target”
  - Different studies may be required to support minimal and desired targets
  - Frequently, the minimal target represents a shorter path to licensure, and post-licensure studies are conducted to incorporate additional targets

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Desired Target</th>
<th>Minimally Acceptable Product</th>
<th>Studies that support the target</th>
</tr>
</thead>
</table>
The TPP Today

The TPP has evolved into a strategic document that is widely used by product developers and has expanded to incorporate additional product attributes not covered by the labeling.

- Marketing attributes
  - Competitive advantage relative to competitor products, cost to produce versus anticipated sale price
- Corporate attributes
  - Portfolio management, ROI
- Governmental/medical affairs
  - Potential for reimbursements
  - Assessment of product uptake by medical providers and public
Benefits of Using a TPP

• Delineates information needed for product success
• Aids product development team in specifying product characteristics to ensure appropriate studies
• Serves as a benchmark and tracks changes to the plan, and rationale for changes
## Benefits of a TPP

<table>
<thead>
<tr>
<th></th>
<th>Without a TPP – claims are broad and non-specific</th>
<th>With a TPP – claims are well-defined and quantifiable</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Label Claims</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Vaccine against chickenpox”</td>
<td>80% efficacy in healthy adults &gt;18 after 3 doses</td>
<td>Defines requirements for efficacy study</td>
<td></td>
</tr>
<tr>
<td>Storage conditions?</td>
<td>Stable at 2°C-8°C for 2 years</td>
<td>Defines formulation and stability requirements</td>
<td></td>
</tr>
<tr>
<td><strong>Marketing Concepts</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost?</td>
<td>&lt;$2.00/dose</td>
<td>Defines requirements for manufacturing and packaging</td>
<td></td>
</tr>
<tr>
<td><strong>Public Perception</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Everyone will want this vaccine”</td>
<td>Requires 80% uptake for commercial success Requires recommendation by vaccine advisory groups</td>
<td>Defines needed market research studies</td>
<td></td>
</tr>
</tbody>
</table>

Note: The TPP defines the studies that are needed to achieve the desired product
### An Example – Influenza Virus Vaccine

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Desired Target</th>
<th>Minimally Acceptable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy</strong></td>
<td>Prevention of influenza disease caused by virus types contained in the vaccine</td>
<td>Demonstration of immune response to antigens in the vaccine that meet requirements of FDA Guidance (accelerated approval without clinical data)</td>
</tr>
<tr>
<td></td>
<td>Efficacy ≥ licensed product</td>
<td></td>
</tr>
<tr>
<td><strong>Target population</strong></td>
<td>Individuals &gt;6 months old</td>
<td>Individuals &gt;18 years old</td>
</tr>
<tr>
<td><strong>Components</strong></td>
<td>HA antigens from four influenza strains (quadrivalent)</td>
<td>HA antigens from three influenza strains</td>
</tr>
<tr>
<td></td>
<td>Preservative-free</td>
<td>Preserved with thimerosal</td>
</tr>
<tr>
<td><strong>Product presentation</strong></td>
<td>• 10-dose vial, preserved</td>
<td>10-dose vial, preserved</td>
</tr>
<tr>
<td></td>
<td>• Single-dose, no preservative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Intradermal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• High Dose</td>
<td></td>
</tr>
<tr>
<td><strong>Shelf life</strong></td>
<td>One year (to cover one flu season)</td>
<td>6 weeks</td>
</tr>
</tbody>
</table>

Each of the targets represents a label claim that must be supported by the appropriate data set. Frequently, the minimal target represents a shorter path to licensure, and post-licensure studies are conducted to incorporate additional targets. The TPP should describe the specific studies that are required to meet both targets.
### Attributes of a Vaccine TPP

<table>
<thead>
<tr>
<th>Labelling Concepts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
</tr>
<tr>
<td>Target population</td>
</tr>
<tr>
<td>Components (description)</td>
</tr>
<tr>
<td>Product presentation</td>
</tr>
<tr>
<td>Route and method of administration</td>
</tr>
<tr>
<td>Shelf-life and storage</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Attributes</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO prequalification</td>
</tr>
<tr>
<td>Registration pathway</td>
</tr>
<tr>
<td>Target price</td>
</tr>
</tbody>
</table>

Specific attributes to include in a TPP are product and project specific – a strategic decision by the project team.
Developing a TPP

• Should be developed with input from all stakeholders
  • Regulatory, commercial, government affairs, clinical, intellectual property, external interested parties

• Identifies characteristics of a minimally acceptable product and the optimal product

• A living document: reviewed and updated periodically

• Specific attributes and the level of details depend on:
  • Nature of the product
  • Stage of product development
Preparing a TPP

Identify cross-functional project team

Assess project status

Agree upon sections and assign authors

Draft criteria for optimal and minimal acceptable targets

Describe studies required for each target

Review and revise criteria

Approve TPP, incorporate into project plan

Review and revise at defined intervals and as data becomes available

• Confirm that development is addressing targets
When Should a TPP Be Developed?

- No specific time that a TPP is required
- Earlier TPP helps minimize the risk of irrelevant activities and increase the likelihood that meaningful preclinical and clinical studies are conducted
Developing a TPP for an HIV vaccine candidate

• Complex development problem
  • Candidates in clinical trials since the 1980s
  • Multiple candidates and studies completed and ongoing
  • No clear consensus on the required immune response, and what vaccine is needed to drive this response
• General consensus that relative to other vaccines
  • the vaccine will be complex and multi-component
  • the immunization regimen will involve multiple doses over a long interval
Expanding the indication and target population

Gardasil as an example

- **2006**: Approval in 2006 for vaccination in females 9-26 for prevention of specified diseases caused by HPV Types 6, 11, 16, and 33

- **2008**: Approval for additional indications in females 9-26 (vulvar/vaginal cancer)

- **2009**: Approval in males 9-26 for prevention of genital warts

- **2011**: Inclusion of information on safety, immunogenicity and key efficacy data in women 27-45 to inform patients and physicians
Acknowledgement

These slides were created as part of the Timely Topics initiative of the Global HIV Vaccine Enterprise in preparation for the Product Development Boot Camp held in New York on 5-6 November, 2015.

We would like to thank Jane Halpern (National Institute of Health) for her time and effort spent on creating this slide set.